Updated POLLUX results for early relapsed myeloma patients

VJHemOnc has 1608 videos Subscribe Here

Description: Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, updates us at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, on the results from the POLLUX trial (NCT02076009). Dr Usmani describes the overall median survival, median progression-free survival, and measurable residual disease data in early relapsed myeloma patients receiving daratumumab, lenalidomide and dexamethasone treatment.
Shared By : VJHemOnc
Posted on : 10/10/18
Added : 11 months ago
Category : Multiple Myeloma